Tillotts Pharma AG

NEWARK, DE, USA I June 12, 2024 I Mage Biologics announces it has dosed the first study participant in a first-in-human study of MB-001, a best-in-class orally administered antibody designed for the treatment of inflammatory bowel disease (IBD). The trial is a randomised, double-blind phase 1 study to assess the safety and pharmacokinetics of single and multiple ascending doses of MB-001 in adult healthy volunteers (NCT06363383). Mage plans to complete the study in the first half of 2025. Johannes Spleiss, CEO of Mage, commented: “We are excited to have been able to move MB-001 into the clinic in a very short period of time and are grateful for the strong support of the experienced Tillotts team that enabled us to quickly produce GMP-grade material for this novel delayed- and sustained-release formulation. Despite more options today for patients with IBD, there still remains a need for safe and highly effective treatments, particularly for the elderly. MB-001 offers the potential to be such an option either as a stand-alone therapy or in combination with current treatments.” Alimentiv, a specialty GI-focused clinical research organisation (CRO) specialised in clinical trial delivery, medical imaging solutions and precision medicine services, provided an excellent project team with deep gastrointestinal expertise that seamlessly integrated into our newly created organisation. Mage Biologics also engages with Chorus, a full-service autonomous research and development unit within Eli Lilly and Company, to support an innovative clinical plan in collaboration with an international network of ulcerative colitis (UC) experts. About ulcerative colitis UC is an inflammatory bowel disease (IBD) that impacts millions of people worldwide. UC affects the innermost lining of the colon and the rectum, causing inflammation and ulcers in the digestive tract. In most people, symptoms usually develop over time, taking a relapsing-remitting course, which means that periods of flare-ups are followed by periods of remission. This can be draining and, in some cases, lead to life-threatening complications. While there is no known cure, current treatments aim to reduce signs and symptoms of the disease and bring remission. Over the last decade, biologics have gained an important place in the treatment of UC, with several monoclonal antibodies available as subcutaneous or intravenous therapies approved for use in UC. Unfortunately, a substantial proportion of patients do not respond, lose response or develop intolerance to currently marketed products, leading to a substantial unmet medical need for safer, effective and more convenient therapeutic options. About MB-001 MB-001 is a best-in-class orally administered, humanised antibody formulation designed for targeted release in the inflamed mucosa, optimal tissue penetration by active receptor-mediated transport, improved potency compared to systemically applied antibodies and optimised receptor interaction by a modified glycosylation pattern. The drug was designed to exert its action in the inflamed tissue with minimal systemic uptake. About Mage Biologics Inc Mage Biologics is a special purpose company created to develop a novel, orally administered monoclonal antibody to clinical proof of concept for the treatment of UC. Mage Biologics is jointly funded by TVM Life Science Innovation II and Tillotts Pharma, and is led by an experienced management team. About Tillotts Pharma Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with close to 400 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialisation of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD and Clostridioides difficile infection (CDI) as well as in-licensed products in around 65 countries through its affiliates within Europe and a network of partners throughout the world. Visit: www.tillotts.com . About TVM Capital Life Science TVM is a leading international venture capital firm focused on investing in life sciences innovations. The company has a highly experienced transatlantic investment team and approximately $900m under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care. TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics. The TVM investment team has worked together for over a decade to effectively utilise this innovative approach to maximise returns for investors and finance new therapies and technologies to meaningfully improve patient lives. Visit: https://tvm-capital.com . SOURCE: Mage Biologics

Pratteln, Switzerland, December 7, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer (CCO) and of Marc Schrader to Chief Technology Officer (CTO). Both will join the six-member Executive Committee effective January 1, 2024. “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by the European Commission. In a staged roll-out across the key European markets, launches will follow in the UK and France later that year, with Spain and Italy scheduled to launch in early 2025,” said Dario Eklund, CEO of Santhera. “With Geert Jan and Marc joining the Executive Committee, we are leveraging the existing expertise within our leadership team and are elevating the commercial and supply chain functions to their level of importance as we enter the commercial market.” Geert Jan van Daal, MD, PhD, has held various senior strategic marketing and commercial roles during his eight years at Santhera. Notably, he was instrumental in establishing Santhera’s European commercial operations and successfully launching the rare disease product RAXONE® in Europe which was later divested to Chiesi Group. His past roles included Head European Affiliates & EU Market Access, Head Europe Western Region and General Manager France & Benelux, as well as being a member of the management team. Before joining Santhera, Geert Jan held positions as Medical Director, Business Unit Director and General Manager in start-up teams in Serono, Actelion and InterMune. He successfully launched and marketed products in a wide variety of rare and orphan diseases in neurology, pediatric diseases, endocrinology, pulmonology, cardiology, rheumatology, metabolic disease and neuro-ophthalmology. Geert Jan completed his medical studies in Rotterdam with a MD degree in 1992 and he also holds a PhD from Erasmus University Rotterdam in The Netherlands. Marc Schrader joined Santhera Pharmaceuticals as Head of Technical Development & Operations in September 2022 and has over 20 years of experience in the pharmaceutical industry. He has extensive expertise in CMC, dealing with complex global pharmaceutical development programs of new chemical entities (small molecules) in early and late clinical stage, clinical and commercial production, product life cycle management, outsourcing and CDMO management, CMC due diligence, CMC regulatory affairs and cGMP. Prior to joining Santhera, Marc held diverse leadership roles in pharmaceutical development, CMC and drug product operations for small molecules across several organizations including Tillotts Pharma AG, Actelion Pharmaceuticals Ltd and Janssen Pharmaceutica N.V./Johnson & Johnson. Marc is a Pharmacist by training and holds a degree in pharmaceutical medicine from the European Center of Pharmaceutical Medicine (ECPM). The CVs of Santhera's senior executives can be viewed on the Company's website here. About Santhera Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved by the U.S. Food and Drug Administration (FDA); in Europe, the marketing authorization application (MAA) has received a positive opinion from the European Medicines Agency’s CHMP in October 2023, and is under review by the UK Medicines and Healthcare products Regulatory Agency (MHRA). Santhera has out-licensed rights to vamorolone for North America to Catalyst Pharmaceuticals and for China to Sperogenix Therapeutics. The clinical stage pipeline also includes lonodelestat to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases. For further information, please visit . AGAMREE® is a trademark of Santhera Pharmaceuticals. Disclaimer / Forward-looking statements This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements. # # # Attachment 2023 12 07_ExecComm_e_final

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announced the strengthening of its management team with the appointment of Edouard Bieth as Chief Business Officer and member of the Executive Committee. Stanislas Veillet, Chief Executive Officer of Biophytis, stated: "Over the past two years, Biophytis has made significant progress in the development of its key asset Sarconeos (BIO101). Our COVA programme in severe forms of COVID-19 has demonstrated its efficacy in a phase 2/3 study and we are currently discussing the next steps with the regulatory authorities, in particular the implementation of early access for patients in France and Brazil. Meanwhile, our SARA programme in sarcopenia has obtained authorization to start a phase 3 trial in the United States and Belgium. In this context, the arrival of Edouard Bieth as Chief Business Officer is a key element in accelerating the availability of our drug candidates. He will lead our market access and commercialisation strategy and will be responsible for establishing partnerships with a view to co-development and licensing agreements for our two key programmes. I am delighted to welcome him to the team, who will benefit from his experience and extensive knowledge of the pharma/biotech ecosystem." A recognised industry leader with over 18 years' experience in the pharmaceutical industry, Edouard Bieth has held a number of senior management positions and has developed strong expertise in market access and sales and marketing strategy, both globally and locally. He will be a member of the Executive Committee and will report directly to Stanislas Veillet, Chairman and CEO of Biophytis. Most recently Edouard spent 6 years as General Manager France & BeNeLux of Tillotts Pharma's commercial subsidiary. During his career, Edouard has also worked for various industry players, including AstraZeneca, Servier and Menarini. He has a Master's degree in biology and pharmacology of ageing and trained in sales and marketing strategy at HEC Paris and in finance at the London Business School. Biophytis has also appointed Claudia Ferreira as Medical Director, reporting to Rob Van Manen, Chief Medical Officer, to strengthen links with the medical community and unite experts around our development programmes, which address major unmet medical needs in severe age-related diseases. About BIOPHYTIS Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. Sarconeos (BIO101), our lead drug candidate, is a small molecule in development for age-related neuromuscular (sarcopenia and Duchenne muscular dystrophy) and cardiorespiratory (Covid-19) diseases. Promising clinical results were obtained in the treatment of sarcopenia in an international phase 2 study, enabling the launch of a phase 3 study in this indication (SARA project). The safety and efficacy of Sarconeos (BIO101) in the treatment of severe COVID-19 were studied in a positive international phase 2-3 clinical trial (COVA project). A pediatric formulation of Sarconeos (BIO101) is currently being developed for the treatment of Duchenne Muscular Dystrophy (DMD, MYODA project). The company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and the ADSs (American Depositary Shares) are listed on Nasdaq Capital Market (Ticker BPTS - ISIN: US09076G1040). For more information, visit Disclaimer This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» section from the Company's 2022 Financial Report available on BIOPHYTIS website ( ) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. Biophytis contacts Investor relations Nicolas Fellmann, CFO Investors@biophytis.com Media Antoine Denry:antoine.denry@taddeo.fr- +33 6 18 07 83 27 Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50 SOURCE: Biophytis View source version on accesswire.com: